I agree. People selling at this price are doing so on the basis that HMD and e-lovu will fail to execute meaningfully on anything (or the usual CR shenanigans). The only way the company is actually worth less than the current market cap over the med-long term is if nothing materialises. I.e. e-lovu fails, JHC/RHC fails, GC trial doesn’t commercialise, no other trials commercialise.
